Literature DB >> 9125615

The incidence of the factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis.

D S Dizon-Townson1, L M Nelson, H Jang, M W Varner, K Ward.   

Abstract

OBJECTIVE: A common missense mutation in the factor V gene, the Leiden mutation, renders factor Va resistant to cleavage inactivation by activated protein C and predisposes patients to thrombotic events. We sought to evaluate the prevalence of the Leiden mutation and the associated thromboembolic events in a community hospital's low-risk obstetric population. STUDY
DESIGN: Deoxyribonucleic acid was extracted from whole blood of 407 women. The polymerase chain reaction was used to amplify exon 10 of the factor V gene, followed by enzymatic digestion with MnI 1 for mutation detection. Medical charts were reviewed and patient characteristics, including age, gravidity, parity, obstetric complications, medical complications, and mode of delivery, were recorded.
RESULTS: Fourteen of the 407 women carried the factor V Leiden mutation (13 heterozygotes and 1 homozygous mutant) for an allele frequency of 3%, consistent with the published carrier rate. Four of the 14 carriers (28%) had deep venous thrombosis, whereas the frequency of deep venous thrombosis in this obstetric population was <1%. Another patient carrying the mutation had a consumptive coagulopathy of unknown etiology at 20 weeks' gestation, necessitating delivery.
CONCLUSIONS: The Leiden mutation is relatively common in the general obstetric population. The high rate of deep venous thrombosis noted in our series suggests the need for genetic testing for this mutation in women with a thrombotic event during pregnancy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9125615     DOI: 10.1016/s0002-9378(97)70615-x

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  5 in total

1.  Impact of smoking during pregnancy on functional coagulation testing.

Authors:  Donna Dizon-Townson; Connie Miller; Valerija Momirova; Baha Sibai; Catherine Y Spong; George Wendel; Katharine Wenstrom; Philip Samuels; Steve Caritis; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Deborah Conway; Ronald J Wapner; Steven G Gabbe
Journal:  Am J Perinatol       Date:  2011-08-04       Impact factor: 1.862

2.  Genetic abnormalities and pregnancy loss.

Authors:  Nathan R Blue; Jessica M Page; Robert M Silver
Journal:  Semin Perinatol       Date:  2018-12-19       Impact factor: 3.300

Review 3.  The effect of factor V Leiden carriage on maternal and fetal health.

Authors:  Dena Bloomenthal; Peter von Dadelszen; Robert Liston; Laura Magee; Peter Tsang
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

Review 4.  Methods of symptom evaluation and their impact on peripheral artery disease (PAD) symptom prevalence: a review.

Authors:  Erica N Schorr; Diane Treat-Jacobson
Journal:  Vasc Med       Date:  2013-03-18       Impact factor: 3.239

5.  Bemiparin versus enoxaparin as thromboprophylaxis following vaginal and abdominal deliveries: a prospective clinical trial.

Authors:  Shahla K Alalaf; Rojan K Jawad; Parez R Muhammad; Mahabad S Ali; Namir G Al Tawil
Journal:  BMC Pregnancy Childbirth       Date:  2015-03-28       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.